Contact hours available until 9/27/2014. Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure: Presenters have no disclosures to declare.
Resolution of Conflict of Interest: The resolutions of conflicts of interest are completed during the planning process. It is the responsibility of the nurse planner to identify and resolve any conflicts prior to implementation of the learning activity.
When a conflict of interest is noted during the planning process, the nurse planner will actively involve the speaker, presenter or author in the resolution of the identified conflict of interest.
The resolution process for a conflict of interest will be documented in the activity file. The potential conflict of interest will be outlined to the planner/presenter/author on the Disclosure Form. The purpose of the disclosure is not to prevent a presenter/ content expert from presenting, but rather to provide the learners with information from which they may make their own decisions. Relevant relationships or potential COI will be identified to learners through a disclosure process.
Commercial Support and Sponsorship: Supported by an educational grant from Takeda Affymax.
Non-Endorsement of Products: Accreditation of activities for contact hours does not imply approval or endorsement of any product, advertising, or educational content by the American Nephrology Nurses' Association (ANNA), or the American Nurses Credentialing Center’s Commission on Accreditation.
Accreditation Statement: American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Accreditation status does not imply endorsement by ANNA or ANCC of any commercial product.
ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.
Discuss hemoglobin variability and its effect on patient outcomes in ESRD patients.
Describe the impact of Hepcidin in the role of iron hemostasis.
Recognize effective treatment strategies to minimize hypo-responsiveness to anemia management.